Ohio State University   

Ohio State University Tumor Boards

Questions discussed in this category


Would you consider afatinib? Afatinib has shown some activity in NRG1 fusion + patients but amplifications is unclear. 

38 y/o female had a biopsy of a palpable mass that showed G3 IDC with 80% ER+, 90% PR+, and HER2 positive (IHC 2+; 1.6 HER2/CEP17 ratio and 6.3 HER2 c...

Would you offer this patient chemotherapy? What are your thoughts about OFS plus AI and avoiding chemotherapy?

 Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients  th...

Are there any data to support a specific TKI therapy for non-T90M exon 20 mutations/insertions? 

For patients with low risk, early stage, hormone receptor positive, HER2 negative breast cancer who initiated endocrine therapy in order to delay thei...

Does tumor size impact your recommendation? High grade? Young patient age?

Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?

Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?

Especially if you don't have trials available at the moment. Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line ge...

In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...

The NCCN guidelines regard  MET exon 14 skip mutation   as an emerging biomarker but no formal recommendation to start crizotinib. If high P...

Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/pa...

Following SRS to the brain lesions, is it safe to closely follow the patient for recurrence?  

 If so, would you treat as node + BC with  anthracycline and taxane regimen or   non-anthracycline regimen (i.e  docetaxel and cyc...

Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung canc...

Is there a point at which there may be no benefit? More than 3 months from breast surgery? 6 months? 1 year?

Would you maintain dose density of chemotherapy and use peg-filgrastim prior to delivery of the baby? Would you defer taxane and anti-HER2 therapy unt...

If so, what would be the regimen that you would consider and what factors would sway you for or against chemotherapy for such patients?

No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.

Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?

PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?

Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would ...

Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...


Papers discussed in this category


Science translational medicine, 2013-12-18

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-02

Cancer, 2004-10-15

Annals of internal medicine, 2018-01-16

Cancer, 2006-09-15

Cancer Discov,

Clin. Cancer Res.,

N. Engl. J. Med.,

The New England journal of medicine, 2016-07-21

The Lancet. Oncology, 2019-01

Eur. J. Cancer, 2017 Aug 04

J Thorac Oncol, 2018 Feb

N. Engl. J. Med.,

NPJ breast cancer, 2017

The New England journal of medicine, 2018-06-14

The New England journal of medicine, 2016-11-17

The Lancet. Oncology, 2016-04

Breast cancer research : BCR, 2016-06-28

The New England journal of medicine, 2016-11-10

The New England journal of medicine, 2018-05-31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-03-01

J. Clin. Oncol., 2017 Oct 02

N. Engl. J. Med., 2017 Jun 04

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-04-15

The New England journal of medicine, 2019-06-20

The New England journal of medicine, 2018-07-12

The New England journal of medicine, 2018-01-11

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019-08-01

Nat Commun, 2019 Mar 27

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Cancer, 2005-04-15

Cancer, 2017-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-20

Lancet (London, England), 2019-05-04

JAMA, 2014-05-21

Clin. Cancer Res., 2019 Aug 15

Ann. Oncol.,

Cancer discovery, 2015-08

Annals of oncology : official journal of the European Society for Medical Oncology, 2018-10-01

Nature, 2014-07-31

Cancer discovery, 2015-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

N Engl J Med,

Lancet Oncol.,

The New England journal of medicine, 2016-03-03

Cancer immunology, immunotherapy : CII, 2017-01

Cancer, 2017-06-01

J Immunother,

Oncologist, 2020 Feb 11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

Breast Cancer Res, 2020 Nov 04

Breast Cancer Res Treat, 2011 Jul 27

Clin Breast Cancer, 2019 May 24

J Clin Oncol, 2021 Feb 04

The New England journal of medicine, 2018-12-06

Lancet, 2019 Oct 04

Ann Oncol, 2019 Oct 1

Int J Cancer, 2020 Dec 21

Adv Ther, 2020 Oct 29